July 29 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS - ANNOUNCES NP-120, ITS LEAD COMPOUND IN IDIOPATHIC PULMONARY FIBROSIS (IPF) RESEARCH PROGRAM, IS A DRUG CALLED IFENPRODIL
* ALGERNON - SINCE NP-120 (IFENPRODIL) IS ALREADY APPROVED WITH ESTABLISHED SAFETY HISTORY, CO INTENDS TO MOVE DRUG DIRECTLY INTO PHASE II HUMAN TRIAL